VF
BCLI

Virtu Financial’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Virtu Financial’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,306
Closed -$17K – 1372
2024
Q2 		$17K Buy
+3,306
New +$24.8K ﹤0.01% 1054
2024
Q1 		– Sell
-4,732
Closed -$19K – 1415
2023
Q4 		$19K Buy
+4,732
New +$14.2K ﹤0.01% 1326
2023
Q3 		– Sell
-726
Closed -$22K – 1312
2023
Q2 		$22K Buy
+726
New +$30.1K ﹤0.01% 1244
2022
Q3 		– Sell
-1,380
Closed -$57K – 1730
2022
Q2 		$57K Buy
+1,380
New +$62.1K ﹤0.01% 1089
2021
Q1 		– Sell
-1,632
Closed -$111K – 1601
2020
Q4 		$111K Buy
+1,632
New +$222K 0.01% 1030
2019
Q4 		– Sell
-867
Closed -$51K – 1440
2019
Q3 		$51K Buy
+867
New +$51.1K ﹤0.01% 1190
2017
Q4 		– Sell
-838
Closed -$52K – 2367
2017
Q3 		$52K Buy
+838
New +$54.2K ﹤0.01% 2220

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Virtu Financial's BCLI Position: Q3 2024 in Review

Virtu Financial sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2024, closing a stake of 3,306 shares — an estimated $17K sold.

Virtu Financial first reported a position in BCLI in Q3 2017 and held it in 7 quarters. The position peaked at $111K in Q4 2020. 38 funds tracked by Wall St. Rank hold BCLI as of Q3 2024.

  • Virtu Financial reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2024 after selling out during the quarter.
  • Virtu Financial sold 3,306 BRAINSTORM CELL THERAPUTC shares in Q3 2024, an estimated $17K.
  • Virtu Financial first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2017 and held it in 7 quarters.
  • Virtu Financial's BRAINSTORM CELL THERAPUTC position peaked at $111K in Q4 2020.
  • 38 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2024.

Based on Virtu Financial's 13F filing for Q3 2024, filed 20 Nov 2024.